As biotherapeutics evolve toward bispecific, trispecific, and Fc-fusion formats, maintaining the binding affinity of each binding arm has become a critical quality attribute (CQA) to monitor from the earliest stages of cell line development (CLD). Yet conventional ELISA-based assays, which require purified samples and offer limited throughput, can create a bottleneck when large numbers of candidate clones must be evaluated.
This whitepaper explores how Samsung Biologics has integrated high-throughput binding affinity assessment based on bio-layer interferometry (BLI), using the Octet® HTX platform, into its clone screening workflow to select clones that deliver both high productivity and binding quality comparable to the reference standard.
Key highlights include:
Label-free binding analysis of up to 96 biosensors simultaneously, directly from crude cell culture supernatants without purification
Relative binding comparison against a reference standard, allowing a full screening panel to be completed within a single day
A case study uncovering the dual-site binding mechanism of an Fc-fusion protein and linking a site-specific loss of binding affinity to glycosylation differences
A case study pinpointing the unstable binding arm of an asymmetric bispecific antibody within hours, without developing new antigen-specific ELISAs
A two-tiered, quality-driven clone screening workflow that combines high-throughput BLI with in-depth analytics such as ELISA and LC-MS
Discover how integrating binding affinity data early in CLD can help identify the right clones sooner and support the development of complex next-generation biotherapeutics.
As biotherapeutics evolve toward bispecific, trispecific, and Fc-fusion formats, maintaining the binding affinity of each binding arm has become a critical quality attribute (CQA) to monitor from the earliest stages of cell line development (CLD). Yet conventional ELISA-based assays, which require purified samples and offer limited throughput, can create a bottleneck when large numbers of candidate clones must be evaluated.
This whitepaper explores how Samsung Biologics has integrated high-throughput binding affinity assessment based on bio-layer interferometry (BLI), using the Octet® HTX platform, into its clone screening workflow to select clones that deliver both high productivity and binding quality comparable to the reference standard.
Key highlights include:
Label-free binding analysis of up to 96 biosensors simultaneously, directly from crude cell culture supernatants without purification
Relative binding comparison against a reference standard, allowing a full screening panel to be completed within a single day
A case study uncovering the dual-site binding mechanism of an Fc-fusion protein and linking a site-specific loss of binding affinity to glycosylation differences
A case study pinpointing the unstable binding arm of an asymmetric bispecific antibody within hours, without developing new antigen-specific ELISAs
A two-tiered, quality-driven clone screening workflow that combines high-throughput BLI with in-depth analytics such as ELISA and LC-MS
Discover how integrating binding affinity data early in CLD can help identify the right clones sooner and support the development of complex next-generation biotherapeutics.
Related Content